8247 — BioSino Bio-technology and Science Balance Sheet
0.000.00%
Last trade - 00:00
- HK$81.04m
- HK$219.36m
- CNY373.07m
- 17
- 58
- 10
- 14
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 34.6 | 54.5 | 45.5 | 44.5 | 77.3 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 142 | 273 | 242 | 257 | 247 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 433 | 426 | 387 | 408 | 397 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 264 | 122 | 130 | 107 | 85.2 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 776 | 645 | 625 | 608 | 603 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 371 | 363 | 379 | 389 | 346 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 474 | 470 | 447 | 432 | 397 |
Common Stock | |||||
Retained Earnings (Accumulated Deficit) | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 302 | 175 | 177 | 176 | 206 |
Total Liabilities & Shareholders' Equity | 776 | 645 | 625 | 608 | 603 |
Total Common Shares Outstanding |